Meus Peptídeos
PerformanceBremelanotide, Vyleesi

PT-141

Peptide melanocortin MC4R receptor agonist, FDA-approved for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. The only approved medication that acts on the central nervous system to increase sexual desire.

Last updated:: 06/04/2026

Research Status

Pré-clínicoFase 1Fase 2Fase 3Aprovado

ANVISA (Brazil)

Not regulated

FDA (USA)

Approved

EMA (Europe)

Not regulated

Mechanism of Action

PT-141 (bremelanotide) activates the melanocortin MC4R receptor in the central nervous system, specifically in hypothalamic areas associated with sexual response. Unlike medications such as sildenafil (Viagra), which acts on blood flow, PT-141 acts directly on the brain circuits of sexual desire.

Study Protocols

Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.

Disfunção sexual feminina (HSDD)

Subcutânea (SC)
1
Protocolo sob demanda1,75 mgSob demanda (mín. 24h entre doses) · Conforme necessidade

Aplicar 45 min antes da atividade sexual

Bremelanotida. Aprovado pelo FDA (Vyleesi). Agonista do receptor MC4R. Não mais que 8 doses/mês.

Benefits

HSDD treatment in women

Proven

RECONNECT studies (phase 3) demonstrated a significant increase in sexual desire and reduction in distress in women with HSDD. FDA-approved in 2019.

View study

Erectile dysfunction in men

Under research

Phase 2 studies showed efficacy in male erectile dysfunction, but development was discontinued in favor of the female market.

Risks and Side Effects

Nausea

Moderate(40% of patients)

Most common side effect. Can be significant and is a reason for discontinuation in some patients.

Blood pressure increase

Moderate(Transient)

Transiently raises blood pressure. Contraindicated in uncontrolled hypertension and cardiovascular disease.

Hyperpigmentation

Low(Uncommon)

May cause skin darkening in exposed areas due to melanocortin receptor activation in the skin.

Internet vs. Science

What people say online compared to the actual scientific evidence.

Female Viagra

Partially true

What they claim

PT-141 is Viagra for women — take it and it's solved.

Actual evidence

FDA-approved for female HSDD, but the mechanism is completely different from Viagra. It acts on the brain (desire), not blood flow (erection). Efficacy is modest — NNT of ~8 (need to treat 8 women for 1 to have clinically significant benefit). Significant side effects.

Studies and References (1)

Bremelanotide for Hypoactive Sexual Desire Disorder (RECONNECT)

Kingsberg SA, Clayton AH, Portman D, et al.Obstetrics & Gynecology (2019) — n=1247

Randomized Clinical Trial

Bremelanotide melhorou significativamente desejo sexual e reduziu distress em mulheres com HSDD em dois estudos de fase 3 (n=1,247).

PubMed

Frequently Asked Questions

Is PT-141 legal in Brazil?

Vyleesi (bremelanotide) is not registered with ANVISA. In the US, it has been FDA-approved since 2019 for HSDD in premenopausal women. It is administered via self-administered subcutaneous injection.

Important notice

This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.

How to Obtain

This compound can be prepared by licensed compounding pharmacies with a valid prescription. Consult a physician first.